Physician profile
Khurram Moin
NPI 1710980974
$9,490.73
in general payments reported to CMS, 2019-2025
22 companies · $656 in 2025
The $656 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,710 · 2020: $2,341 · 2021: $264 · 2022: $731 · 2023: $3,188 · 2024: $600 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502 · Travel and Lodging: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.83 |
| Travel and Lodging | $1,942.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $3,065.29 | 2022-2023 | Indigo System, Penumbra System |
| Medtronic Vascular, INC. | $1,027.92 | 2019-2020 | |
| Cardiovascular Systems INC. | $1,010.95 | 2019-2020 | |
| Abiomed | $842.13 | 2019-2025 | Impella |
| Siemens Medical Solutions USA, INC. | $552.17 | 2019-2022 | |
| Medtronic, INC. | $522.17 | 2021-2025 | Hawkone, Corevalve Evolut R, Resolute Onyx |
| Abbott Laboratories | $461.97 | 2020-2023 | Confirm Rx |
| Amarin Pharma, INC. | $269.17 | 2019 | |
| Shockwave Medical, INC | $254.49 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $250.38 | 2019-2025 | |
| Pfizer INC. | $186.73 | 2019-2023 | |
| Boston Scientific Corporation | $186.72 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $162.35 | 2022-2025 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.32 | 2023-2025 | Lifevest |
| Cvrx, INC. | $133.56 | 2023-2024 | Barostim Neo System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $127.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $91.73 | 2019-2020 | |
| Philips North America LLC | $84.59 | 2019 | |
| Merck Sharp & Dohme LLC | $36.77 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $32.29 | 2022-2025 | Camzyos |
| Genzyme Corporation | $22.99 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $18.16 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khurram Moin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.